Terms: = Sarcomas AND PRKAR1A, DKFZp779L0468, 5573, ENSG00000108946, PRKAR1, P10644, CNC1, PKR1, MGC17251, PPNAD1, TSE1, CNC, CAR AND Prognosis
23 results:
1. Chimeric antigen receptor T cells in the treatment of osteosarcoma (Review).
Yu T; Jiang W; Wang Y; Zhou Y; Jiao J; Wu M
Int J Oncol; 2024 Apr; 64(4):. PubMed ID: 38390935
[TBL] [Abstract] [Full Text] [Related]
2. Current status and future challenges of car-T cell therapy for osteosarcoma.
Li S; Zhang H; Shang G
Front Immunol; 2023; 14():1290762. PubMed ID: 38187386
[TBL] [Abstract] [Full Text] [Related]
3. Surfaceome Profiling of Cell Lines and Patient-Derived Xenografts Confirm FGFR4, NCAM1, CD276, and Highlight AGRL2, JAM3, and L1CAM as Surface Targets for Rhabdomyosarcoma.
Timpanaro A; Piccand C; Uldry AC; Bode PK; Dzhumashev D; Sala R; Heller M; Rössler J; Bernasconi M
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768928
[TBL] [Abstract] [Full Text] [Related]
4. A new model of preoperative systemic inflammatory markers predicting overall survival of osteosarcoma: a multicenter retrospective study.
Huang X; Liu Y; Liang W; Luo K; Qin Y; Li F; Xie T; Qin H; He J; Wei Q
BMC Cancer; 2022 Dec; 22(1):1370. PubMed ID: 36585638
[TBL] [Abstract] [Full Text] [Related]
5. Modulation of immunosuppressive cells and noncoding RNAs as immunotherapy in osteosarcoma.
Xia Y; Wang D; Piao Y; Chen M; Wang D; Jiang Z; Liu B
Front Immunol; 2022; 13():1025532. PubMed ID: 36457998
[TBL] [Abstract] [Full Text] [Related]
6. Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?
Rémond MS; Pellat A; Brezault C; Dhooge M; Coriat R
ESMO Open; 2022 Dec; 7(6):100638. PubMed ID: 36399952
[TBL] [Abstract] [Full Text] [Related]
7. CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response.
Boudin L; de Nonneville A; Finetti P; Mescam L; Le Cesne A; Italiano A; Blay JY; Birnbaum D; Mamessier E; Bertucci F
J Transl Med; 2022 Oct; 20(1):464. PubMed ID: 36221119
[TBL] [Abstract] [Full Text] [Related]
8. DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms.
Yao J; Bergsland E; Aggarwal R; Aparicio A; Beltran H; Crabtree JS; Hann CL; Ibrahim T; Byers LA; Sasano H; Umejiego J; Pavel M
Oncologist; 2022 Nov; 27(11):940-951. PubMed ID: 35983951
[TBL] [Abstract] [Full Text] [Related]
9. The clinical significance of perioperative inflammatory index as a prognostic factor for patients with retroperitoneal soft tissue sarcoma.
Matsui Y; Matsuda A; Maejima A; Shinoda Y; Nakamura E; Komiyama M; Fujimoto H
Int J Clin Oncol; 2022 Jun; 27(6):1093-1100. PubMed ID: 35319075
[TBL] [Abstract] [Full Text] [Related]
10. car T targets and microenvironmental barriers of osteosarcoma.
Zhu J; Simayi N; Wan R; Huang W
Cytotherapy; 2022 Jun; 24(6):567-576. PubMed ID: 35193828
[TBL] [Abstract] [Full Text] [Related]
11. Targeting the tumor microenvironment of Ewing sarcoma.
Morales E; Olson M; Iglesias F; Luetkens T; Atanackovic D
Immunotherapy; 2021 Dec; 13(17):1439-1451. PubMed ID: 34670399
[TBL] [Abstract] [Full Text] [Related]
12. A Novel Treatment for Ewing's Sarcoma: Chimeric Antigen Receptor-T Cell Therapy.
Lin Z; Wu Z; Luo W
Front Immunol; 2021; 12():707211. PubMed ID: 34566963
[TBL] [Abstract] [Full Text] [Related]
13. ERBB2-car-Engineered Cytokine-Induced Killer Cells Exhibit Both car-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma.
Merker M; Wagner J; Kreyenberg H; Heim C; Moser LM; Wels WS; Bonig H; Ivics Z; Ullrich E; Klingebiel T; Bader P; Rettinger E
Front Immunol; 2020; 11():581468. PubMed ID: 33193388
[TBL] [Abstract] [Full Text] [Related]
14. Interaction of BACH2 with FUS promotes malignant progression of glioma cells via the TSLNC8-miR-10b-5p-WWC3 pathway.
Yang Y; Liu X; Zheng J; Xue Y; Liu L; Ma J; Wang P; Yang C; Wang D; Shao L; Ruan X; Liu Y
Mol Oncol; 2020 Nov; 14(11):2936-2959. PubMed ID: 32892482
[TBL] [Abstract] [Full Text] [Related]
15. Relapsed Osteosarcoma Trial Concepts to Match the Complexity of the Disease.
Reed DR; Hingorani P; Anderson PM
Adv Exp Med Biol; 2020; 1257():85-94. PubMed ID: 32483733
[TBL] [Abstract] [Full Text] [Related]
16. CD56-chimeric antigen receptor T-cell therapy for refractory/recurrent rhabdomyosarcoma: A 3.5-year follow-up case report.
Jiang C; Zhao W; Qin M; Jin M; Chang L; Ma X
Medicine (Baltimore); 2019 Oct; 98(43):e17572. PubMed ID: 31651858
[TBL] [Abstract] [Full Text] [Related]
17. Elimination of Osteosarcoma by Necroptosis with Graphene Oxide-Associated Anti-HER2 Antibodies.
Xiao H; Jensen PE; Chen X
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31491952
[TBL] [Abstract] [Full Text] [Related]
18. B7-H3 and its role in bone cancers.
He L; Li Z
Pathol Res Pract; 2019 Jun; 215(6):152420. PubMed ID: 31060912
[TBL] [Abstract] [Full Text] [Related]
19. Clinical significance of traditional clinical parameters and inflammatory biomarkers for the prognosis of patients with spinal chondrosarcoma: a retrospective study of 150 patients in a single center.
Xu K; Li B; Huang Q; Jiang D; Sun H; Zhong N; Wan W; Wei H; Xiao J
Eur Spine J; 2019 Jun; 28(6):1468-1479. PubMed ID: 31055664
[TBL] [Abstract] [Full Text] [Related]
20. [RETRACTED: Recommandations françaises du Comité de Cancérologie de l’AFU — Actualisation 2018—2020 : sarcomes rétropéritonéaux French ccAFU guidelines — Update 2018—2020: Retroperitoneal sarcoma].
Murez T; Savoie PH; Fléchon A; Durand X; Rocher L; Camparo P; Morel-Journel N; Ferretti L; Sèbe P; Méjean A
Prog Urol; 2018 Nov; 28(12S):S165-S174. PubMed ID: 30473000
[TBL] [Abstract] [Full Text] [Related]
[Next]
